1	Obstructive sleep apnea is associated with specific gut microbiota species and functions in
2	the population-based Swedish CardioPulmonary bioImage Study (SCAPIS)
3	Gabriel Baldanzi <sup>1</sup> , Sergi Sayols-Baixeras <sup>1,2</sup> , Jenny Theorell-Haglöw <sup>1,3</sup> , Koen F Dekkers <sup>1</sup> , Ulf
4	Hammar <sup>1</sup> , Diem Nguyen <sup>1</sup> , Yi-Ting Lin <sup>1,4,5</sup> , Shafqat Ahmad <sup>1,6</sup> , Jacob Bak Holm <sup>7</sup> , Henrik Bjørn
5	Nielsen <sup>7</sup> , Louise Brunkwall <sup>8</sup> , Christian Benedict <sup>9</sup> , Jonathan Cedernaes <sup>10,11</sup> , Sanna Koskiniemi <sup>12</sup> ,
6	Mia Phillipson <sup>11</sup> , Lars Lind <sup>13</sup> , Johan Sundström <sup>13,14</sup> , Göran Bergström <sup>15,16</sup> , Gunnar Engström <sup>8</sup> , J
7	Gustav Smith <sup>17,18,19</sup> , Marju Orho-Melander <sup>8</sup> , Johan Ärnlöv <sup>4,20</sup> , Beatrice Kennedy <sup>1</sup> , Eva
8	Lindberg <sup>3†</sup> , and Tove Fall <sup>1†*</sup> .
9	
10	<sup>1</sup> Department of Medical Sciences, Molecular Epidemiology and Science for Life Laboratory,
11	Uppsala University, Uppsala, Sweden;
12	<sup>2</sup> CIBER Cardiovascular diseases (CIBERCV), Instituto de Salud Carlos III, Madrid, Spain
13	<sup>3</sup> Department of Medical Sciences, Respiratory, Allergy and Sleep Research, Uppsala
14	University, Uppsala, Sweden;
15	<sup>4</sup> Division of Family Medicine and Primary Care, Department of Neurobiology, Care Science and
16	Society, Karolinska Institute, Huddinge, Sweden;
17	<sup>5</sup> Department of Family Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical
18	University, Taiwan
19	<sup>6</sup> Preventive Medicine Division, Harvard Medical School, Brigham and Women's Hospital,
20	Boston, United States
21	<sup>7</sup> Clinical Microbiomics A/S, Copenhagen, Denmark;
22	<sup>8</sup> Department of Clinical Sciences in Malmö, Lund University Diabetes Center, Lund University,
23	Malmö, Sweden;

- <sup>9</sup>Molecular Neuropharmacology (Sleep Science Lab), Department of Pharmaceutical
- 25 Biosciences, Uppsala University, Uppsala, Sweden;
- <sup>10</sup>Department of Medical Sciences, Transplantation and regenerative medicine, Uppsala
- 27 University, Uppsala, Sweden;
- <sup>11</sup>Department of Medical Cell Biology and Science for Life Laboratory, Uppsala University,
- 29 Uppsala, Sweden;
- <sup>30</sup> <sup>12</sup>Department of Cell and Molecular Biology, Uppsala University, Uppsala, Sweden;
- <sup>13</sup>Department of Medical Sciences, Clinical Epidemiology, Uppsala University, Uppsala,
- 32 Sweden;
- <sup>14</sup>The George Institute for Global Health, University of New South Wales, Sydney, Australia
- <sup>15</sup>Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy,
- 35 University of Gothenburg, Gothenburg, Sweden;
- <sup>16</sup>Department of Clinical Physiology, Sahlgrenska University Hospital, Region Västra Götaland,
- 37 Gothenburg, Sweden;
- <sup>17</sup>The Wallenberg Laboratory/Department of Molecular and Clinical Medicine, Institute of
- 39 Medicine, Gothenburg University and the Department of Cardiology, Sahlgrenska University
- 40 Hospital, Gothenburg, Sweden;
- 41 <sup>18</sup>Department of Cardiology, Clinical Sciences, Lund University and Skåne University Hospital,
- 42 Lund, Sweden;
- 43 <sup>19</sup>Wallenberg Center for Molecular Medicine and Lund University Diabetes Center, Lund
- 44 University, Lund, Sweden;
- 45 <sup>20</sup>School of Health and Social Studies, Dalarna University, Falun, Sweden
- 46 \* Corresponding author

- 47 <sup>†</sup> Shared senior authorship.
- 48
- 49 Corresponding author:
- 50 Tove Fall, EpiHubben, Uppsala University
- 51 751 85 Uppsala, Sweden
- 52 Email: tove.fall@medsci.uu.se
- 53

### 54 Abstract

55 Obstructive sleep apnea (OSA) is a common sleep-related breathing disorder. In animal models, OSA has been shown to alter the gut microbiota; however, little is known about such effects in 56 57 humans. Here, we used respiratory polygraphy data from 3,570 individuals aged 50–64 from the 58 Swedish CardioPulmonary bioImage Study (SCAPIS) and deep shotgun metagenomics to 59 identify OSA-associated gut microbiota features. We found that OSA-related hypoxia parameters 60 were associated with 128 bacterial species, including positive associations with *Blautia obeum* 61 and *Collinsela aerofacines*. The latter was also associated with increased systolic blood pressure. 62 Further, the cumulative time in hypoxia was associated with nine gut microbiota metabolic 63 pathways, including propionate production from lactate, a biomarker of hypoxia. In conclusion, in this first large-scale study on gut microbiota alterations in OSA, we found that OSA-related 64 hypoxia is associated with specific microbiota features. Our findings can direct future research 65 on microbiota-mediated health effects of OSA. 66

### 68 Introduction

Obstructive sleep apnea (OSA) is characterized by upper airway collapse episodes during sleep 69 70 resulting in complete cessation (apneas) or reduction (hypopneas) of air flow and consequent 71 intermittent hypoxia<sup>1</sup>. It is estimated that OSA affects 5–36% of the adult population, depending 72 on the country studied and the diagnostic criteria used. The increasing prevalence of OSA has 73 been attributed to the increased longevity worldwide and the rising prevalence of obesity<sup>2</sup>, a 74 well-described cause of OSA<sup>3</sup>. Although OSA has been prospectively associated with 75 cardiovascular disease independent of BMI<sup>4,5</sup>, the mechanisms are not yet fully elucidated<sup>6</sup>. 76 The most commonly used clinical parameter of OSA severity is the apnea-hypopnea-77 index (AHI), which quantifies the number of apnea and hypopnea events per hour of sleep. 78 However, AHI does not differentiate short apnea events with mild oxygen desaturation from 79 prolonged events with severe hypoxia<sup>7</sup>. To quantify the time in hypoxia during sleep, the 80 assessment for OSA often measures the percentage of the sleep time with oxygen saturation 81 <90% (T90). The T90 parameter is a more reliable metric of nocturnal hypoxia intensity but 82 not always associated with AHI<sup>8</sup>. Lastly, the oxygen desaturation index (ODI), which quantifies 83 the number of oxygen desaturation events per hour of sleep<sup>9</sup>, is considered the most suitable parameter when the sole purpose is to measure intermittent hypoxia<sup>10</sup>. In sum, the three 84 85 parameters are complementary to each other as they capture different dimensions of OSA. 86 The microbiota is a complex microbial community that interacts continuously with the 87 host<sup>11</sup>. Studies of animal models of OSA have found that intermittent hypoxia and intermittent 88 airway obstruction can produce substantial changes in the gut microbiota composition<sup>12–15</sup>. In 89 turn, alterations of the gut microbiota induced by OSA may partly mediate the effects of OSA on 90 adverse health outcomes, including the development of hypertension<sup>15–17</sup>. Smaller studies in humans have linked OSA to the microbiota composition in the upper airways  $(n = 92)^{18}$  and in 91

92	the gut $(n = 113)^{19}$ . However, these studies did not adjust for important confounders, such as diet
93	and medications, and were limited in their taxonomic resolution of the microbiota.
94	To overcome the above limitations, there is a need for adequately powered investigations
95	of the associations between OSA and the human gut microbiota, combining extensive
96	information on confounding factors with species-level microbiota data. Here, we used a validated
97	method suitable for population-wide screening for OSA (ApneaLink Air®, ResMed, CA,
98	USA) <sup>20,21</sup> to investigate how key prognostic and severity features of OSA were cross-sectionally
99	associated with the human gut microbiota, analyzed with shotgun metagenomic sequencing in up
100	to 3,570 participants from the large population-based Swedish CardioPulmonary BioImage
101	Study (SCAPIS). We found that all three OSA parameters were associated with lower gut
102	microbiota richness and evenness, as measured with the Shannon index. In addition, T90 was
103	independently associated with 59 specific bacterial species and ODI was independently
104	associated with 97 species. We further found that the T90-associated microbiota were enriched
105	for nine microbial metabolic pathways. One of the T90-associated species, Collinsella
106	aerofaciens, was also associated with systolic blood pressure independent of BMI, the OSA
107	parameters, and related risk factors. These findings may guide future research on the role of the
108	gut microbiota as a potential mediator of OSA-associated morbidities.

### 109 **Results**

### 110 **Descriptive statistics**

111 After excluding the participants who reported use of continuous positive air pressure (CPAP) as

- 112 treatment for OSA (n = 59), the study sample consisted of 3,175 (54% female) SCAPIS
- 113 participants with valid AHI data (Fig. S1) and 3,570 (52% female) with valid T90 and ODI data.
- 114 The mean age was 57.7 years. The Spearman's correlation coefficient between the OSA

parameters was 0.56 for AHI and T90; 0.92 for AHI and ODI; and 0.63 for T90 and ODI.

- 116 Population characteristics are described in Table 1, as well as in Tables S1 and S2.
- 117

### 118 OSA is associated with lower gut microbiota richness and evenness

119 To investigate whether OSA was associated with the richness and evenness of the gut

120 microbiota, we performed partial Spearman's correlation analyses of the three OSA parameters

121 a) AHI, b) T90, and c) ODI with alpha diversity measured as the Shannon index<sup>22</sup>. We used a

122 hypothetical causal diagram (Fig. S2) and the d-separation criterion<sup>23</sup> to identify the minimal set

123 of confounders for adjustment in our main model. Thus, covariates in the main model consisted

124 of age, sex, smoking, alcohol intake, and BMI, as well as the DNA extraction plate to account for

125 variation between batches. We found that AHI, T90, and ODI were inversely associated with the

126 Shannon index (AHI:  $\rho = -0.058$ , p-value = 0.002; T90:  $\rho = -0.043$ , p-value = 0.013, ODI:  $\rho = -$ 

127 0.065, p-value =  $1.75 \times 10^{-4}$ , Table S3). To better account for the influence of diet and other

128 confounders, we also constructed an extended model with additional adjustments for calculated

129 fiber intake and total energy intake from a food frequency questionnaire, self-reported leisure

130 time physical activity, education level, country of birth, and season of assessment. In this

131 extended model, the associations were somewhat attenuated (AHI:  $\rho = -0.047$ , p-value = 0.013;

132 T90:  $\rho = -0.038$ , p-value = 0.034, ODI:  $\rho = -0.055$ , p-value = 0.002). Taken together, these

133 results indicate a decreased gut microbiota richness and evenness in OSA.

134

### 135 Gut microbiota composition differs by OSA severity independently of BMI

136 To determine whether the OSA severity was associated with the overall gut microbiota

137 composition, we analyzed the beta diversity measured as Bray-Curtis dissimilarity in relation to

138 groups of AHI, T90, and ODI. Starting with AHI, we grouped the participants (n=3,175) with 139 valid AHI data according to previously established and clinically used cut-off values<sup>24</sup> (no OSA: 140 AHI < 5, n = 1,851; mild: AHI 5–14.9, n = 899; moderate: AHI 15–29.9, n = 295; severe: AHI  $\geq$ 141 30, n = 130). To graphically represent the relationship between the groups, we conducted a 142 principal coordinate analysis on the Bray-Curtis dissimilarity matrix (Fig. 1a). We observed a 143 separation of the groups along the first axis in order of severity. This separation was supported 144 by the results of a permutational analysis of variance (PERMANOVA) adjusted for the main model covariates ( $R^2 = 0.5\%$  and p-value = 0.0001). In pairwise comparisons (Table S4), we 145 146 found some evidence supporting a difference for all pairwise comparisons (nominal p-value < 147 (0.05), except between the groups mild and severe (p-value = 0.26), probably due to higher 148 dispersion and lower power in this comparison. Taken together, these results suggest that the 149 groups of OSA severity based on AHI have different gut microbiota compositions. 150 To assess whether the gut microbiota composition also differed among participants 151 depending on their hypoxia parameters, we divided the participants with available T90 and ODI 152 data (n=3,570) into four groups. Because there were no well-established cut-offs, we aim to 153 create groups of similar sizes. Due to the high proportion of participants with T90 = 0, grouping 154 by quartiles was not possible for this variable. Therefore, we performed the following division 155 for T90: one group of participants with T90 = 0 (n=1,088), and the remaining participants 156 divided into three groups of similar size in order of ascending T90 values: t1 = 912 individuals 157 (T90: 1-3%), t2 = 759 (T90: 4-14%), and t3 = 811 (T90: 15-100%). For ODI, we divided the 158 participants by quartiles: q1 = 913 individuals (ODI: 0–1.8), q2 = 885 (ODI: 1.9–4.3), q3 = 891159 (ODI: 4.4–9.4), and q4 = 881 (ODI: 9.5–93). Either based on T90 or ODI, the groups separated 160 along the first axis in order of severity in the principal coordinate analysis (Fig. 1b and 1c). We

161	confirmed the separations using PERMANOVA (T90 groups: $R^2 = 0.2\%$ and p-value = 0.013.
162	ODI groups: $R^2 = 0.3\%$ and a p-value = 0.002). In the pairwise comparisons of T90 groups
163	(Table S4), we found that the group with $T90 = 0$ differed from the t2 and t3 groups (p-values =
164	0.001 and 0.006, respectively). In the pairwise comparisons of ODI groups (Table S4), we found
165	that the q1 group differed from the q3 and q4 groups (p-values = $0.014$ and $0.001$ , respectively).
166	We also found a difference between the q2 and q4 groups (p-value = $0.005$ ).
167	
167	We additionally investigated differences in the overall gut microbiota between the groups
168	We additionally investigated differences in the overall gut microbiota between the groups after adjusting for the extended model covariates. For all grouping strategies; i.e., AHI-, T90- or
168	after adjusting for the extended model covariates. For all grouping strategies; i.e., AHI-, T90- or
168 169	after adjusting for the extended model covariates. For all grouping strategies; i.e., AHI-, T90- or ODI-based, we confirmed the differences in gut microbiota composition across groups (AHI

173 composition – as assessed with Bray-Curtis dissimilarity – across groups of OSA ordered by 174 severity. The difference between groups was clearer when using the pre-established AHI cut-offs 175 rather than the similarly sized groups based on T90 and ODI. We could still detect differences in 176 the gut microbiota composition between groups of T90 or ODI even after accounting for several 177 confounders.

178

# OSA-related hypoxia is associated with the relative abundance of specific gut microbiota species independently of BMI, dietary fiber intake, and common medications

181 To study how the OSA parameters AHI, T90, and ODI were associated with the relative

abundance of gut microbiota species, we performed a series of partial Spearman's correlations

183 with each OSA parameter and each species. Given that BMI may influence or be influenced by

the abundance of gut microbiota species<sup>25</sup> and that obesity is an important cause of OSA<sup>3</sup>, BMI could either be considered a confounder or a source of reverse causation in the association of OSA with microbiota. Therefore, we divided the main model into two: one model not including, and one model including BMI. The model not including BMI was then used as a screening step to select the species that would be taken into the subsequent models. We defined significance using p-values adjusted for multiple comparisons, referred to here as q-values, with a false discovery rate set at 5%.

191 Without adjustment for BMI, we found that AHI was associated with the relative 192 abundances of 566 species, T90 with 631 species, and ODI with 692 species (Fig. 2a and Table 193 S5). Next, the species that were associated with at least one of the OSA parameters in this step 194 were analyzed with the main model including BMI. In these analyses, AHI was associated with 195 101 species, T90 with 141, and ODI with 241 (Table S6). When assessing the overlap of these 196 associations, we found that the three OSA parameters were jointly associated with the relative 197 abundances of 53 species. The AHI and ODI parameters were jointly associated with another 42 198 species, ODI and T90 were jointly associated with another 46 species, and AHI and T90 were 199 jointly associated with one other species (Fig. 2b).

To account for other potential confounders, the species associated with at least one of the OSA parameters in the main model not including BMI were then analyzed with the extended model. In these analyses, AHI was no longer associated with any species (Fig. 2c and Table S7). Nevertheless, T90 was associated with 59 species, of which 17 were positive, and ODI with 97 species, of which 17 were positive. The parameters T90 and ODI were jointly positively associated with six species, including the species *Blautia obeum* (internal identifier: HG3A.0001), *Ruminococcus gnavus, Coprococcus comes*, and the recently isolated

207 *Mediterraneibacter glycyrrhizinilyticus*<sup>26</sup>. The T90 and ODI parameters were jointly negatively 208 associated with 22 unidentified species, of which 16 belonged to the order Eubacteriales. Based 209 on the correlation coefficients, the strongest positive associations with ODI were 210 *Fusicatenibacter saccharivorans* ( $\rho = 0.069$ , q-value = 0.008), and an unidentified species of the 211 family *Lachnospiraceae* (HG3A.0018,  $\rho = 0.069$ , q-value = 0.008). Among the 17 positive 212 associations with ODI, 10 species belonged to the family Lachnospiraceae. The strongest 213 negative association of ODI was with an unidentified *Eubacteriales* sp. (HG3A.0069,  $\rho = -0.074$ , 214 q-value = 0.006). The strongest positive association of T90 was with *Dorea formicigenerans* ( $\rho$ 215 = 0.086, q-value = 0.001), followed by *B. obeum* (HG3A.0001,  $\rho = 0.079$ , q-value = 0.003). The 216 strongest negative association was with *Eubacteriales* sp. (HG3A.0703,  $\rho = -0.073$ , q-value = 217 0.009). 218 One possible explanation for the null findings for AHI was that fewer participants had 219 valid AHI data compared with the number of participants with valid T90 and ODI data. To 220 ascertain that the null findings were not due to lower power, we conducted a secondary analysis 221 where we used multiple imputations to impute missing AHI values for the 340 participants who

had valid T90 or ODI values, but not valid AHI values. Even in this secondary analysis, we did not observe any associations between AHI and species after adjustment for the extended model covariates (Table S8).

Next, we performed a series of sensitivity analyses with the 128 species associated with T90 and/or ODI in the extended model to investigate how medication use or presence of lung disease affected our findings (Table S9). Firstly, we added to the extended model the covariates of metformin use, and proton pump inhibitor (PPI) use, based on measurable metabolomic plasma levels of these medications, as well as self-reported medication use for hypertension

230	and/or hyperlipidemia. All 128 species remained associated with T90 and/or ODI after the
231	additional adjustment (q-value $< 0.05$ ). After excluding the 367 participants who had used any
232	antibiotic during the six months before sampling, all associations were retained, except for the
233	association between ODI and Eubacteriales sp. (HG3A.0691). The result also did not change
234	after excluding the 29 participants with self-reported diagnosis of chronic obstructive pulmonary
235	disease (COPD), chronic bronchitis, or pulmonary emphysema. Altogether, this series of
236	analyses highlighted the robustness of the associations between the hypoxia parameters T90 and
237	ODI and the identified species. In summary, we found that the OSA-related hypoxia parameters
238	were robustly associated with 127 gut microbiota species.
239	
240	The T90 and ODI associations with gut microbiota species were not modified by
241	hemoglobin levels
242	Exposure to hypoxia increases erythropoiesis and results in increased hemoglobin levels <sup>27</sup> . In
243	turn, hemoglobin level affects the oxygen delivery to tissues <sup>28</sup> . To assess the effect modification
244	by hemoglobin levels on the T90 and ODI associations with the gut microbiota species, we
245	conducted Spearman's correlation analyses adjusted for the extended model covariates stratified
246	by the sex-specific median hemoglobin value. These analyses included the 128 species that we
247	identified as being associated with the T90 and/or ODI parameters (Table S10). In the
248	association between ODI and Eubacteriales sp. (HG3A.1026), we detected a difference in the
249	correlation estimates between participants with high or low hemoglobin status ( $\rho_{low} = 0.008$ , p-
250	value <sub>low</sub> = 0.75 and and $\rho_{high}$ = -0.12, p-value <sub>high</sub> =1.8×10 <sup>-6</sup> , heterogeneity q-value = 0.02).
251	Differences were also observed for other species, as in the association between ODI and
252	Clostridia sp. (HG3A.0140, $\rho_{low} = -0.12$ , p-value <sub>low</sub> = 4.0×10 <sup>-6</sup> and $\rho_{high} = -0.02$ , p-value <sub>high</sub> =

0.36), but when we formally tested for these differences, we could not confirm them
(heterogeneity q-value > 0.05). Therefore, we could not ascertain whether hemoglobin levels
acted as an effect modifier on the associations between OSA-related hypoxia parameters and the
gut microbiota species abundance.

257

### 258 **T90-associated gut microbiota showed enriched putative metabolic pathways**

259 To characterize the putative metabolic profile of the species associated with OSA, we performed 260 enrichment analyses to identify overrepresented metabolic pathways among the AHI, T90, or 261 ODI associations with gut microbiota species (extended model). Metabolic pathways were 262 defined using the gut metabolic modules (GMM)<sup>29</sup>. We found no metabolic pathways enriched in 263 the AHI or ODI associations (Table S9). The positive associations between T90 and the gut 264 microbiota species were enriched for nine metabolic pathways (Fig. 3a), including threonine degradation I and II (q-value =  $9.3 \times 10^{-4}$  and 0.02, respectively), and propionate production II (q-265 266 value = 0.02). The latter is comprised of the enzyme propionate CoA-transferase, which 267 produces propionate from lactate<sup>30</sup>. The pathway threonine degradation I consists of a series of 268 enzymatic steps that metabolize L-threonine into propionate. One of the these steps is carried out 269 by the activated pyruvate-formate lyase, which is only activated under anaerobic conditions<sup>31</sup>. 270 The T90-species associations were also enriched for lysine degradation II (q-value = 0.004), 271 serine degradation (q-value = 0.009), and the pathways of carbohydrate degradation: 272 galacturonate degradation I (q-value < 0.001, and ribose degradation (q-value = 0.047). 273 Our results on the enrichment of microbial metabolic pathways suggest that the duration 274 of hypoxia during sleep, as reflected by the T90 parameter, may favor gut microbiota species

with specific metabolic repertoires. Noteworthy, we found that T90 was associated with the

production of propionate from lactate, a biomarker of hypoxia. On the other hand, we could not
find evidence that AHI or ODI were associated with metabolic features of the gut microbiota.

279 Species positively associated with T90 and/or ODI have different metabolomic fingerprints

### 280 than those negatively associated

281 To characterize the metabolomic fingerprint of the 128 gut microbiota species associated with

282 T90 and/or ODI in the extended model, we mined data from the online GUTSY Atlas

283 (<u>https://gutsyatlas.serve.scilifelab.se/</u>), which has investigated the associations between the

human gut microbiota and the plasma metabolome in a cohort that also included participants

from the current study<sup>32</sup>. From the GUTSY Atlas, we retrieved data on the enrichment analyses

for metabolite groups in the associations between the species and the plasma metabolites. The

analyses were conducted stratified by the direction of the associations.

288 In the heatmaps of enriched metabolite groups for every species, we observed a different 289 pattern of enrichment for the 100 species that had a negative association with T90 and/or ODI 290 values compared with the 28 species that had a positive association with these parameters. For 291 instance, while several positively-associated species were positively associated with secondary 292 bile acids (Fig. 4b), the negatively-associated species were negatively associated with these 293 metabolites (Fig. 4a). A similar pattern was also observed for dihydrosphingomyelins and 294 phosphatidylcholine metabolites. In addition, for 19 species that were negatively associated with 295 T90/ODI, we found enrichment for vitamin A metabolites; whereas four species in positive 296 association with T90/ODI had a negative association with vitamin A metabolites. 297 Lastly, we found evidence that the species that were negatively associated with the

298 hypoxia parameters T90 or ODI were also negatively associated with tobacco metabolites.

Although these species were identified in analyses adjusted for smoking status, it is possible that these species may also have a reduced abundance in smokers, hence the negative association with tobacco metabolites.

302 Overall, our results indicated that the associations between the species and the plasma 303 metabolites had opposite directions depending if the species abundance was expected to increase 304 or decrease with hypoxia. The main differences in the metabolomic fingerprints involved the 305 pattern of association with vitamin A metabolites, dihydrosphingomyelins, secondary bile acids, 306 phosphatidylcholine, and tobacco metabolites.

307

## 308 Microbiota species associated with OSA-related hypoxia and were also associated with 309 blood pressure

310 Previous studies have found that OSA is associated with increased risk for insulin resistance<sup>33</sup> 311 and incident blood hypertension<sup>4</sup>. Furthermore, fecal microbiota transplantation studies in mice 312 have suggested that alterations in the gut microbiota induced by OSA might contribute to the 313 detrimental health effects of OSA<sup>15,16</sup>. Therefore, we investigated whether the 128 T90/ODI-314 associated species and the nine T90-enriched metabolic pathways were also associated with 315 blood pressure measurements (n = 2,335) and glycated hemoglobin (Hb1Ac, n = 2,786). We 316 excluded from the association analyses with blood pressure measurements the participants who 317 self-reported medication for hypertension. Likewise, we excluded from the analyses with HbA1c 318 the participants who self-reported medication for diabetes. Based on a directed acyclic graph 319 (Fig. S3), the associations were adjusted for age, sex, alcohol intake, smoking, fiber intake, total 320 energy intake, leisure time physical activity, country of birth, ODI, AHI, T90, and DNA 321 extraction plate. Among the species negatively associated with T90 or ODI, 19 were negatively

322	associated with systolic blood pressure (Fig. 3b), including Intestinimonas massiliensis ( $\rho = -$
323	0.07, q-value = $0.02$ ), and nine were negatively associated with diastolic blood pressure (Table
324	S12). Among the positive associations, the species Collinsella aerofaciens, and the microbial
325	pathway threonine degradation I were positively associated with systolic and diastolic blood
326	pressure. None of the species or microbiota functions investigated were associated with Hb1Ac.
327	In the analyses additionally adjusted for BMI, C. aerofaciens continued to associate with
328	systolic blood pressure ( $\rho = 0.073$ , q-value = 0.034) and <i>Eubacteriales</i> sp. (HG3A.0196)
329	continued to negatively associate with systolic ( $\rho = -0.077$ , q-value = 0.032) and diastolic blood
330	pressure ( $\rho = -0.081$ , q-value = 0.015). Altogether, we could observe that specific species and
331	metabolic pathways previously identified in association with T90 or ODI were also associated
332	with blood pressure measurements in the same direction. Two species continued to be associated
333	with blood pressure measurements even after adjustment for BMI.

### 334 **Discussion**

335 Here we presented the most comprehensive population-based study to date investigating the 336 relationship of OSA with the human gut microbiota. We found evidence that OSA, especially 337 OSA-related hypoxia, was associated with the composition and functional potential of the human 338 gut microbiota. The OSA hypoxia parameters, namely T90 and ODI, were associated with the 339 abundance of specific species after extensive adjustment for potential confounders such as 340 treatment for diabetes, hypertension, hyperlipidemia, and gastritis and gastroesophageal reflux. 341 We further noted enrichment for specific microbial metabolic pathways shared by bacteria 342 positively associated with the duration of hypoxia during sleep. 343 Out of the 128 species associated with T90 and/or ODI, 28 were associated with both

344 parameters. Among the six positive associations, four were annotated to the species level,

345 namely B. obeum, C. comes, R. gnavus, and M. glycyrrhizinilyticus. A higher relative abundance 346 of B. obeum, previously named Ruminococcus obeum, has been observed in individuals with 347 insulin resistance<sup>34</sup>. Nevertheless, we did not find an association between *B. obeum* and HbA1c 348 levels, a marker of glycemic control, in the present study. C. comes is one of the gut microbiota species found to decrease in abundance post bariatric surgery<sup>35</sup>, a procedure known to improve 349 350 many conditions related to obesity, including OSA<sup>36</sup>. R. gnavus, a mucin-degrading microbe, has 351 been positively associated with incident type 2 diabetes in a large Finnish population cohort<sup>37</sup>. 352 These four species all belong to the family *Lachnospiraceae*. An increased abundance of the Lachnospiraceae family has been observed in mice subjected to intermittent hypoxia<sup>12</sup>. Also 353 354 belonging to the same family are *D. formicigenerans* and *Anaerobutyricum hallii*, which were 355 positively associated with T90; and Roseburia inulinivorans, F. saccharivorans, Ruminococcus 356 torques and Blautia massiliensis, which were positively associated with ODI. However, a 357 mechanistic explanation connecting the *Lachnospiraceae* family to host hypoxia is lacking and 358 warrants further investigation. 359 In this study, ODI was positively associated with C. aerofaciens, which was in turn 360 positively associated with systolic blood pressure independent of BMI and OSA. C. aerofaciens is an obligate anaerobe abundant in the human gut<sup>38</sup>, with higher abundance in overweight and 361 362 obese individuals<sup>39</sup>. Higher abundance of C. aerofaciens has also been observed in individuals with type 1 pulmonary hypertension<sup>40</sup>, a condition associated with lower oxygen saturation<sup>41</sup>. 363

364 Longitudinal and experimental studies are necessary to understand whether the gut microbiota

365 species identified in this study may have a role connecting OSA to blood pressure.

The OSA hypoxia parameters T90 and ODI were associated with the abundance of specific species after adjustment for the extended model covariates, while AHI was not. Our

results suggest that OSA-related hypoxia might be of greater importance when it comes to
associations with the gut microbiota than the apnea and hypopnea events themselves. Increasing
attention has been given to OSA-related hypoxia, as recent studies have shown that OSA-related
hypoxia, unlike AHI, predicted increased cardiovascular mortality<sup>5</sup>.

372 Evidence in the literature suggests that intermittent host hypoxia directly affects the gut 373 microbiota. In the study by Moreno-Indias et al., intermittent hypoxia applied during the mice's 374 rest phase resulted in enrichment for gut obligate anaerobes<sup>12</sup>. Similarly, a reduction of 375 anaerobes was observed in the gut microbiota of rats after hyperbaric treatment<sup>42</sup>. In the Moreno-376 Indias et al. study, the authors demonstrated that intermittent hypoxia produced oscillations in 377 the oxygen concentration inside the intestinal lumen close to the epithelium, thus providing a 378 physiological rationale for how the oxygenation level of the host could impact the gut microbiota 379 environment<sup>12</sup>.

380 The identified associations could be due to effects of OSA on sleep fragmentation as both 381 acute and chronic sleep fragmentation have been demonstrated to affect the gut microbiota 382 composition in rodents<sup>43</sup>. Nevertheless, sleep fragmentation alone is unlikely to explain why 383 OSA hypoxia parameters associated with the abundance of specific species while AHI did not. 384 Daytime sleepiness may be a result of sleep fragmentation; however, the Epworth sleepiness 385 scale score, a measurement of daytime sleepiness, was not different between the groups of OSA 386 severity based on T90 (Table S1). To better disentangle the effects of sleep fragmentation due to 387 OSA from the effects of nocturnal hypoxia, future studies would benefit from concomitant 388 electroencephalogram monitoring, polysomnography assessment and actigraphy. 389 One possible indirect mechanism through which OSA might affect the microbiota is

389 One possible indirect mechanism through which OSA hight affect the incrobiota is
 390 through alterations in the host metabolism, such as accumulation of lactate<sup>44</sup>. Experiments in

391 mice using labeled lactate showed that circulating lactate can cross the gut barrier and enter the 392 intestinal lumen<sup>45</sup>. Higher plasma concentration of lactic acid has benn described in OSA 393 patients<sup>46</sup>. Additionally, T90 was positively associated with venous concentration of lactate in treatment-naïve OSA patients<sup>44</sup>. High circulating levels of lactate is also present in athletes 394 395 postexercise; although, in this case, lactate is produced in the absence of hypoxia<sup>47</sup>. A study 396 comparing the gut microbiota in athletes before and after exercise found an increase in microbial 397 genes involved in the conversion of lactated into propionate after exercise<sup>45</sup>. The authors of the 398 latter study hypothesized that the host lactate entering the intestinal lumen could favor bacterial 399 species that use lactate as a carbon source. This hypothesis corresponds with our findings; the 400 pathway of propionate production from lactate was enriched in positive T90 associations with 401 gut microbiota species. In summary, supported by the existing literature, our study suggests an 402 association between the hypoxia caused by OSA, plasma lactate, and the gut microbiota 403 metabolic profile.

404 The strengths of our study include the large sample size, temporal proximity between 405 OSA assessment and fecal microbiota sampling, the extensive adjustment for confounders, and 406 the use of an objective assessment for OSA instead of self-reported diagnosis or a convenience 407 sample of OSA patients. Our investigation on a random sample from the population provides a 408 more generalizable picture of the association between OSA and the gut microbiota than studies 409 comparing controls to patients with a clinical diagnosis of OSA. The combination of a large 410 sample size with shotgun metagenomic sequencing allowed us to conduct a comprehensive 411 investigation at the species level and also of the microbial metabolic profile.

412 Nevertheless, there are limitations that need to be considered when interpreting our
413 results. Because of the cross-sectional design, we were not able to assess causality. Despite the

414 extensive adjustment, we cannot rule out residual confounding. Moreover, even if the animal 415 studies indicate a causal effect of OSA on the gut microbiota, an effect in opposite direction is 416 also plausible. For example, certain gut microbiota species may promote weight gain that may 417 consequently lead to OSA<sup>48</sup>. In this case, BMI would open a pathway for reverse causation from 418 the gut microbiota to the development of OSA. The gut microbiota was examined using fecal 419 shotgun metagenomics followed by detection of species based on the co-abundance of genes. 420 Although valid and well-described<sup>49</sup>, this approach leads to the detection of some incompletely 421 annotated species, which have not yet been isolated and characterized. Alternatively to fecal 422 samples, mucosal biopsies could have provided information on the gut microbiota that resides more closely to the host<sup>50</sup>, thus more likely to be affected by OSA. Our results may not extend to 423 424 populations in other countries due to the close connection between geographical location and the 425 gut microbiota<sup>51</sup>. The ApneaLink Air® two-channel device used to assess sleep apnea does not 426 distinguish obstructive from central apneas. However, obstructive sleep apneas are more 427 common in the general population<sup>52</sup>. An assessment for OSA based on a single night may result 428 in a certain degree of exposure misclassification<sup>53</sup>, which could affect the precision, but would 429 not bias our estimates. The T90 parameter is not able to differentiate hypoxia caused by OSA 430 from nocturnal hypoxia of other etiologies. Finally, we excluded participants that used CPAP, a 431 common treatment for OSA. Thus, future studies should investigate whether the herein observed 432 OSA-gut microbiota associations are affected by OSA therapy, including but not limited to 433 CPAP.

Animal studies have found that comorbidities present in mouse models of OSA can be
 transferred to control mice through fecal microbial transplant<sup>15,17</sup>. Furthermore, observational
 studies have implicated the human gut microbiota in the development of metabolic and

cardiovascular disorders, such as hypertension<sup>54</sup> and insulin resistance<sup>55</sup>. Given the results from
animal and observational studies, it is possible that alterations in the human gut microbiota
caused by OSA could at least in part contribute to the increased risk of cardiovascular disease
seen in OSA patients. Therefore, the associations that we found between OSA and the gut
microbiota can be informative for future research aiming to identify gut microbiota mechanisms
that connect OSA to health outcomes.

443 In conclusion, we present the largest study to date that has investigated the association 444 between OSA and the human gut microbiota. We found that the objective parameters of OSA-445 related hypoxia, namely T90 and ODI, were independently associated with 59 and 97 gut 446 microbiota species, respectively. In addition, we found that the gut microbiota associated with 447 T90 was enriched for nine metabolic pathways, including the pathway for production of 448 propionate from lactate. Our findings provide novel insights into the relationship between OSA 449 and the gut microbiota. Future experimental studies are necessary to validate whether the 450 identified microbial species may represent potential therapeutic targets to prevent or treat 451 comorbidities of OSA.

### 452 Methods

### 453 **Study population**

454 From 2013 to 2018, a total of 30,154 women and men aged 50–64 were enrolled in the SCAPIS

455 study. Participants were randomly invited from the general population across six regions in

456 Sweden<sup>56</sup>. In the Uppsala region, 4,839 participants had data on fecal shotgun metagenomics and

- 457 4,183 were assessed for OSA. Combined, 4,045 participants had both OSA data and
- 458 metagenomic data. We excluded the 59 participants who reported use of CPAP. At least four
- 459 hours of air flow and oxygen saturation recordings were required to compute a valid AHI value

460 and at least four hours of oxygen saturation recording was required to compute valid T90 and

461 ODI values. Therefore, data on AHI were available for 3,175 participants and data on T90 and

462 ODI were available for 3,570 participants (Fig. S1).

- 463 SCAPIS study and the present study were approved by the Swedish Ethical Review
- 464 Authority (DNR 2018-315 B and amendment 2020-06597, and DNR 2010-228-31M,
- 465 respectively). All participants provided informed consent.
- 466

### 467 **OSA assessment**

468 Assessment for OSA was conducted using the ApneaLink Air® (ResMed, CA, USA)<sup>57</sup>. After 469 instructions, participants took the ApneaLink Air® device home for recording of nasal air flow 470 and oxygen saturation during one night's sleep. Apnea was defined as a reduction of breathing 471 flow  $\geq$ 80% for at least 10 seconds. Hypopnea was defined as a period of at least 10 seconds with 472 a decrease in the baseline air flow of 30-80% combined with a decrease  $\geq 4\%$  in oxygen 473 saturation. From the OSA assessment, the variables AHI, T90, and ODI were chosen for the 474 current study as they are clinically relevant measures and commonly used in previous research. 475 The AHI was calculated as the mean number of apneas and hypopneas events per hour of total 476 recording time. Using clinically used cuff-off values, AHI severity groups were defined as no 477 OSA for AHI < 5, mild for AHI 5–14.9, moderate for AHI 15–29.9, and severe for AHI  $\ge$  30<sup>24</sup>. 478 The T90 variable was computed by adding the time spent with an oxygen saturation < 90% and 479 dividing by the total recording time. For the grouping based on T90, the first group was 480 composed of participants with a T90 = 0. The remaining participants were grouped by tertiles. It 481 was not possible to group the participants based on quartiles because > 25% of the participants 482 had a T90 = 0. ODI was calculated as the mean number of desaturation events per hour during

the total recording time. A desaturation event was defined as a decrease from baseline  $\geq 4\%$  in oxygen saturation. For the grouping based on ODI, the participants were divided by quartiles of ODI.

486

### 487 Fecal metagenomic analysis

488 SCAPIS participants were instructed to collect fecal samples into dry tubes at home with the 489 provided kit and store the samples at the home freezer until the study site visit. Median interval 490 between fecal sample collection and OSA assessment was 0 days (IQR: 0–1). The samples were 491 then kept at  $-20^{\circ}$ C at the test centers. After 0–7 days, the samples were shipped to the central 492 biobank where they were kept at  $-80^{\circ}$ C. Next, the samples were sent in dry ice to Clinical 493 Microbiomics A/S (Copenhagen, Denmark) for DNA extraction, shotgun metagenomic 494 sequencing, and taxonomic annotation. Analyses were performed in random order of samples' 495 boxes (16 samples per box) during 2019 and 2020. DNA was extracted from all samples using 496 NucleoSpin<sup>®</sup> 96 Soil kits (740787; Macherey-Nagel; Germany) from the same batch (Lot: 497 1903/001). Each extraction round contained a negative and positive control (ZymoBIOMICS<sup>TM</sup> 498 Microbial Community Standard, D6300, Zymo Research). For cell lysis, a bead beating step was 499 performed for 5 min at 2200 rpm with tubes placed horizontally on the vortex (Vortex-Genie 2). 500 After DNA fragmentation and library preparation, sequencing was performed using an 501 Illumina Novaseq 6000 system (Illumina, USA). On average, 26.3 million read pairs (SD =  $\pm 6.9$ 502 millions) were generated per sample for Uppsala samples. Reads were removed if they contained 503 clear adapter contamination, > 10% ambiguous bases, or > 50% bases with Phred quality score <504 5. Reads pairs were also removed if any of the reads mapped to the human reference genome 505 GRCh38 using Bowtie 2  $(v.02.3.2.)^{58}$ . Reads that passed this quality control were assembled with

506 MEGAHIT (v. 1.1.1)<sup>59</sup> and mapped using BWA-MEM (v. 0.7.16a)<sup>60</sup> to a new gene catalog. This 507 new gene catalog was created using samples from the SCAPIS study, which included samples 508 from Uppsala and Malmö sites, samples from the Malmö Offspring Study (MOS)<sup>61</sup>, samples 509 from Pasolli et al.<sup>62</sup>, and 3,486 publicly available genome assemblies from isolated microbial 510 strains.

511 Co-abundant genes that passed quality assessment were defined as metagenomic species 512 as described in Nielsen et al<sup>49</sup>. Briefly, each metagenomic species has a gene set of 100 signature 513 genes, which are genes selected for optimal and accurate abundance profiling. A metagenomic 514 species was considered detected if read pairs mapped to at least three of the 100 signature genes 515 of that metagenomic species. Then, the total gene counts were used to produce a table of 516 metagenomic species counts, normalized according to read length. Metagenomic species counts 517 were transformed into relative abundances.

518 There were 1,985 species identified with a mean of 355 species detected per Uppsala 519 sample. Considering the Uppsala participants only, species that were present in  $\leq 1\%$  of the 520 participants were removed, resulting in 1,602 species for subsequent analyses. All the negative 521 controls showed no detectable DNA. DNA extraction from positive controls resulted in a 522 positive signal. For the positive controls, the coefficient of variation estimated by the Shannon 523 diversity index was 3.05%. For 158 pairs of biological replicates, the coefficient of variation was 524 1.49%. Clinical Microbiomics was unaware that the replicates were submitted for analysis. 525 The taxonomic annotation of the metagenomic species was performed by mapping the catalog genes to NCBI RefSeq<sup>63</sup> database (downloaded on May 2, 2021). If >75% of the 526 527 metagenomic species genes mapped to a single microbial species, a species-level taxonomy was

528 annotated to that metagenomic species. Different thresholds were used for taxonomic annotation

529	at genus, family, order, class, and phylum level (60, 50, 40, 30, and 25% respectively). However,
530	a species or genus-level annotation was not assigned if $> 10\%$ of the genes mapped to another
531	single species or genus. For functional annotation, the gene catalog was annotated to the
532	EggNOG (v. 5.0) orthologous groups database (http://eggnogdb.embl.de/) using EggNOG-
533	mapper-software (v. 2.0.1) <sup>64</sup> , which provides annotations to the Kyoto Encyclopedia of Genes
534	and Genomes (KEGG) orthology (KO) database (https://www.genome.jp/kegg/). Based on KO
535	annotations, the metabolic potential of the metagenomic species was determined in terms of
536	GMM <sup>29</sup> . As previously described, the GMMs are 103 metabolic pathways, defined as a series of
537	enzymatic steps represented by KO identifiers <sup>29</sup> . A metagenomic species was considered to
538	contain a GMM if it contained at least two-thirds of the KOs of a module. For modules with
539	three or fewer steps, all steps were required. For modules with alternative paths, only one path
540	had to fulfil the criterion. The relative abundance of a GMM was defined as the sum of the
541	relative abundances of all metagenomic species that encoded that module.
542	
543	Anthropometric, sociodemographic, health, and medication information
544	SCAPIS participants answered an extensive questionnaire on demographic information,

education, lifestyle, self-reported health, medication use, as well as a food frequency
questionnaire<sup>65</sup>. Smoking was categorized as never, former, or current smoker. Education was
categorized based on the highest level achieved. The possible education categories were
uncompleted primary or lower secondary education, completed lower secondary education,
upper secondary education, or university education. Leisure time physical activity was selfreported as one of four possible categories: mostly sedentary, moderate but regular exercise,
moderate activity, regular and moderate activity, or regular exercise or training. According to

552 country of birth, participants were categorized into four groups: born in Scandinavia (Sweden, 553 Denmark, Norway or Finland), in Europe, in Asia, or in other countries. From the food frequency 554 questionnaires, variables were calculated to estimate alcohol intake  $(g/day)^{66}$ , fiber intake 555  $(g/day)^{67}$ , and total energy intake  $(kcal/day)^{66}$ . Dietary information was assigned as missing for 556 participants whose ln(total energy intake) was greater than the mean of ln(total energy intake)  $\pm$ 557 3 standards deviations in the study sample. Anthropometric measurements were performed on 558 site. BMI ( $kg/m^2$ ) was calculated as weight divided by the height squared. Systolic and diastolic 559 blood pressure were assessed on site, calculated as the average of two measurements in the arm 560 with the highest mean systolic pressure. 561 Anti-hypertensive medication and medication for hyperlipidemia were categorized as 562 binary variable based on the questionnaire. Use of proton pump inhibitors (PPI) and use of 563 metformin were defined as a binary variable based on the plasma metabolome. Participants with 564 a measurable omeprazole and/or pantoprazole plasma level were classified as PPI users. 565 Participants with a measurable metformin plasma level were classified as metformin users. 566 Information on previous antibiotic use (Anatomical Therapeutical Chemical code J01) was 567 provided by the SCAPIS cohort study after linkage with the Swedish Prescribed Drug Register 568 (https://www.socialstyrelsen.se/en/statistics-and-data/registers/national-prescribed-drug-569 register/). 570

### 571 Plasma metabolome analysis

572 The fasting plasma samples were collected during site visit and stored at -80°C in the central
573 biobank until they were sent in random order to Metabolon Inc. (Durham, NC, USA) for
574 metabolomics profiling, as previously described<sup>32,68</sup>. Briefly, after sample preparation,

metabolomics was conducted using four protocols: reverse phase (RP)/ultrahigh performance
liquid chromatography-tandem mass spectroscopy (UPLC-MS/MS) with negative-ion mode
electrospray ionization (ESI), hydrophilic interaction chromatography (HILIC)/UPLC-MS/MS,
and two separate RP/UPLC-MS/MS resolutions with positive-ion mode ESI. Metabolites were
annotated using Metabolon's in-house compound library <sup>68</sup> . We used the GUTSY Atlas
(https://gutsyatlas.serve.scilifelab.se/) to retrieve information on enrichment for metabolite
groups in the gut microbiota species associations with plasma metabolites <sup>32</sup> .
Statistical analyses
To identify the set of confounders for adjustment, we created a hypothetical causal diagram in
the browser-based application DAGitty 3.0 (www.dagitty.net; Fig. S2) <sup>69</sup> . To investigate the
association between OSA and the gut microbiota, we identified sex, age, smoking, alcohol
intake, and BMI as the minimal sufficient adjustment set. Therefore, these variables were

included in the main model together with DNA extraction plate to account for technical

590

596

589 variation. Age, alcohol intake, and BMI were modelled as continuous variables. Sex and

591 categorical variable with one level per plate (i.e., 52 levels). Given that the hypothetical causal

smoking were modelled as categorical variables. DNA extraction plate was also modelled as a

592 diagram on the effect of OSA on the gut microbiota is rather complex and that confounders such

593 as diet<sup>70</sup> and socioeconomic status<sup>71</sup> were not included in the minimal sufficient adjustment set,

594 we chose to construct an extended model accounting for these factors. Thus, the extended model

- additionally included fiber intake, total energy intake, leisure time physical activity, highest
- 597 modelled as continuous variables. Leisure time physical activity, highest education level, and

26

education level achieved, country of birth, and season. Fiber intake and total energy intake were

598 country of birth were modelled as categorical variables with four levels each. The variable 599 season consisted of 11 categories based on the month of the study site visit. The categories 600 "June" and "July" were merged because there were only four participants for July. 601 Analyses were conducted using the R software version 4.1.1 (https://cran.r-project.org/). 602 Partial Spearman's correlations were performed using the function *pcor.test* in the R package 603 *ppcor*<sup>72</sup>. Gut microbiota beta diversity and alpha diversity were calculated using the package 604 *vegan* version 2.5- $7^{73}$ . For the alpha diversity analyses, the Shannon index<sup>22</sup> was calculated for 605 each participant using the function *diversity*. To investigate how AHI, T90 and ODI were 606 associated with the Shannon index, we used partial Spearman's correlation. The beta diversity 607 was assessed with the Bray-Curtis dissimilarity, which was calculated using the function *vegdist*. 608 PERMANOVA was conducted using the function adonis2 (package vegan) with 9,999 609 permutations assessing the marginal effects of the terms. The Bray-Curtis dissimilarity matrix 610 was set as the outcome and the AHI, T90, or ODI severity groups were set as the main exposure 611 separately. Principal coordinate analysis was conducted using the function *pcoa* from the 612 package  $ape^{74}$ .

613 To investigate how AHI, T90, and ODI associated with the relative abundance of the gut 614 microbiota species, we examined the partial Spearman's correlation between each of the OSA 615 parameters and each of the 1,602 species. To understand the effect of BMI on our results, we 616 first conducted this analysis with the main model not including the covariate BMI. The species 617 identified in this first step were further investigated in two additional analyses: one with all main 618 model covariates, including BMI, and another model including the extended model covariates. 619 Multiple comparison was accounted for using the Benjamini-Hochberg method with a FDR set at 620 5%<sup>75</sup>.

621 The species associated with at least one of the three OSA parameters in the extended 622 model were further examined in three sensitivity analyses. In the first sensitivity analysis, we 623 included to the extended model the variables of medication use, more specifically metformin, 624 PPI, anti-hypertensive medications, and/or medications for hyperlipidemia. In the second 625 sensitivity analysis, we excluded participants (n = 367 among those with valid T90/ODI values) 626 that had used any antibiotic in the previous six months. And in the third sensitivity analysis, we 627 excluded the 29 participants with lung disease, defined as a self-reported diagnosis of COPD, 628 chronic bronchitis, or pulmonary emphysema. After removing these participants, we re-629 conducted the Spearman's correlation analyses adjusting for the extended model covariates. 630 We handled missing data using complete-case analysis; i.e., participants that did not have 631 information for all variables included in a model were removed from that respective analysis. 632 The variable with the highest frequency of missing information was leisure time physical activity 633 followed by smoking, antihypertensive medication use, and use of medication for 634 hyperlipidemia. Of the participants with valid AHI data, 6% were missing information for leisure 635 time physical activity. Information on smoking, anti-hypertensive medication, and medication 636 for hyperlipidemia was missing for 5% of the participants who had valid AHI data. After removing participants with incomplete information on the main model covariates, there were 637 638 3,004 participants for AHI analyses and 3,364 participants for the T90 and ODI analyses. Adding 639 or removing BMI did not change the number of participants included, as this variable was not 640 missing for all participants. For the extended model, after removing participants with incomplete 641 information on covariates, there were 2,909 participants for the AHI analyses and 3,249 642 participants for the T90 and ODI analyses. In the sensitivity analysis adjusting for medication 643 use, there were 3,305 participants for the T90 and ODI analyses.

644 Because of the lower number of participants with valid AHI values than the number of 645 participants with valid T90 and ODI values, we conducted a secondary analysis where we 646 imputed the AHI values for the 340 participants that for whom we had information on T90 and 647 ODI but not on AHI, considering the extended model covariates. This analysis was conducted 648 using the software Stata 15.1 (Stata Corp., Texas, USA). Multiple imputation was conducted 649 using predicted mean matching with the five nearest neighbors and 10 imputations. Variables 650 used for imputation included all extended model covariates, as well as Shannon index, AHI, T90, 651 ODI, waist-hip-ratio, and the species relative abundance. To avoid including all 1,602 species in 652 the same imputation equation, we performed an imputation step for each species, followed by the 653 Spearman's correlation analysis between AHI and the species, adjusted for the extended model 654 covariates. The uncertainty of imputations was accounted for using Rubin's combination rules<sup>76</sup>. 655 The effect modification by hemoglobin level was explored by categorizing participants 656 into low or high hemoglobin groups based on the sex-specific median hemoglobin level. First, 657 we conducted the Spearman's correlation of OSA parameters with species relative abundance 658 stratified by hemoglobin group and adjusted for the extended model covariates. Next, each pair 659 of correlation coefficients obtained from the two groups were compared as described in Altman et al.<sup>77</sup> Briefly, the standard error for each coefficient was estimated using 1,000 bootstrap 660 replications (R package  $boot^{78}$ ). Z-scores were then calculated as the ratio of the difference 661 662 between the two coefficients to the standard error of the difference. The two-sided p-values were 663 then obtained from the standard normal distribution.

For the pathway enrichment analysis for GMM, we used the Spearman's correlation
results from the extended model on the associations of AHI, T90, and ODI with the 1,602
microbiota species. The enrichment analyses were conducted based on ranked p-values using the

R package *fgsea*<sup>79</sup>, stratified by the direction of the correlation coefficients. To investigate the
metabolite groups associated with each T90/ODI-associated species, we retrieved from GUTSY
Atlas<sup>32</sup> the enrichment analysis results for metabolite groups for each of the species.

670 In a post hoc analysis, we used Spearman's correlation to assess the association of our 671 main gut microbiota findings with systolic and diastolic blood pressure, as well as HbA1c. To 672 decide on the set of covariates for adjustment, we created a hypothetical causal diagram of the 673 effect of the gut microbiota on blood pressure and insulin resistance (Fig. S3). Based on the 674 causal diagram, we adjusted the analysis for age, sex, alcohol intake, smoking, fiber intake, total 675 energy intake, leisure time physical activity, country of birth, ODI, T90, and AHI, in addition to 676 DNA extraction plates. Due to the effect of medication on the gut microbiota and the health 677 outcomes of interest, we excluded the participants who self-reported medication use for 678 hypertension from the analyses with blood pressure measurements. In the analyses of the 679 association with HbA1c, we excluded participants who self-reported medication use for diabetes. 680 Using a complete-case analysis, data were available for 2,335 participants for the analyses with 681 blood pressure measurements and for 2,801 participants for the Hb1Ac analyses. Lastly, we 682 assessed the effect of adding BMI to the model.

### 683 Data availability

The anonymized metagenomic sequences can be found in the European Nucleotide Archive under the accession code "PRJEB51353". The individual-level data underlying this article were provided by the SCAPIS cohort study under agreement, after ethical approval, and are not shared publicly due to confidentiality. Data will be shared upon reasonable request to the corresponding author only after permission by the SCAPIS Data access board (https://www.scapis.org/dataaccess/) and by the Swedish Ethical Review Authority (https://etikprovningsmyndigheten.se).

### 690 Code availability

- 691 The code used in the present analyses is available at GitHub
- 692 (https://github.com/MolEpicUU/sleepapnea\_gut)

### 693 **References**

- I. Jordan, A. S., McSharry, D. G. & Malhotra, A. Adult obstructive sleep apnoea. *Lancet Lond. Engl.* 383, 736–747 (2014).
- 696 2. Benjafield, A. V. et al. Estimation of the global prevalence and burden of obstructive sleep
- apnoea: a literature-based analysis. *Lancet Respir. Med.* **7**, 687–698 (2019).
- Schwartz, A. R. *et al.* Obesity and obstructive sleep apnea: pathogenic mechanisms and
  therapeutic approaches. *Proc. Am. Thorac. Soc.* 5, 185–192 (2008).
- Peppard, P. E., Young, T., Palta, M. & Skatrud, J. Prospective study of the association
  between sleep-disordered breathing and hypertension. *N. Engl. J. Med.* 342, 1378–1384
- 702 (2000).
- 5. Azarbarzin, A. et al. The hypoxic burden of sleep apnoea predicts cardiovascular disease-
- related mortality: the Osteoporotic Fractures in Men Study and the Sleep Heart Health Study.
- 705 *Eur. Heart J.* **40**, 1149–1157 (2019).
- 6. Collen, J., Lettieri, C., Wickwire, E. & Holley, A. Obstructive sleep apnea and
- cardiovascular disease, a story of confounders! *Sleep Breath.* **24**, 1299–1313 (2020).
- 708 7. Linz, D. et al. Nocturnal hypoxemic burden is associated with epicardial fat volume in
- patients with acute myocardial infarction. *Sleep Breath.* **22**, 703–711 (2018).
- 710 8. Khoshkish, S. *et al.* The association between different features of sleep-disordered breathing
- and blood pressure: A cross-sectional study. J. Clin. Hypertens. Greenwich Conn 20, 575–
- 712 581 (2018).

- 713 9. Terrill, P. I. A review of approaches for analysing obstructive sleep apnoea-related patterns
  714 in pulse oximetry data. *Respirology* 25, 475–485 (2020).
- 715 10. Rashid, N. H. et al. The Value of Oxygen Desaturation Index for Diagnosing Obstructive
- 716 Sleep Apnea: A Systematic Review. *The Laryngoscope* **131**, 440–447 (2021).
- 717 11. Salvucci, E. The human-microbiome superorganism and its modulation to restore health. Int.
- 718 J. Food Sci. Nutr. **70**, 781–795 (2019).
- 719 12. Moreno-Indias, I. *et al.* Intermittent hypoxia alters gut microbiota diversity in a mouse model
  720 of sleep apnoea. *Eur. Respir. J.* 45, 1055–1065 (2015).
- 13. Lucking, E. F. et al. Chronic intermittent hypoxia disrupts cardiorespiratory homeostasis and
- gut microbiota composition in adult male guinea-pigs. *EBioMedicine* **38**, 191–205 (2018).
- 14. Tripathi, A. et al. Intermittent Hypoxia and Hypercapnia, a Hallmark of Obstructive Sleep

Apnea, Alters the Gut Microbiome and Metabolome. *mSystems* **3**, e00020-18.

15. Durgan, D. J. et al. Role of the Gut Microbiome in Obstructive Sleep Apnea-Induced

726 Hypertension. *Hypertens. Dallas Tex 1979* **67**, 469–474 (2016).

- 16. Khalyfa, A. *et al.* Circulating exosomes and gut microbiome induced insulin resistance in
- mice exposed to intermittent hypoxia: Effects of physical activity. *EBioMedicine* 64, 103208
  (2021).
- 17. Badran, M., Khalyfa, A., Ericsson, A. & Gozal, D. Fecal microbiota transplantation from
- 731 mice exposed to chronic intermittent hypoxia elicits sleep disturbances in naïve mice. *Exp.*
- 732 *Neurol.* **334**, 113439 (2020).
- 18. Hong, S.-N. *et al.* Association of obstructive sleep apnea severity with the composition of the
- <sup>734</sup> upper airway microbiome. J. Clin. Sleep Med. JCSM Off. Publ. Am. Acad. Sleep Med. (2021)
- 735 doi:10.5664/jcsm.9640.

- 19. Ko, C.-Y. et al. Gut microbiota in obstructive sleep apnea-hypopnea syndrome: disease-
- related dysbiosis and metabolic comorbidities. *Clin. Sci. Lond. Engl. 1979* **133**, 905–917
- 738 (2019).
- 739 20. Ng, S. S. S. et al. Validation of a portable recording device (ApneaLink) for identifying
- patients with suspected obstructive sleep apnoea syndrome. *Intern. Med. J.* **39**, 757–762
- 741 (2009).
- Prudon, B., Hughes, J. & West, S. A novel postal-based approach to diagnosing obstructive
  sleep apnoea in a high-risk population. *Sleep Med.* 33, 1–5 (2017).
- 744 22. Spellerberg, I. F. & Fedor, P. J. A tribute to Claude Shannon (1916–2001) and a plea for
- 745 more rigorous use of species richness, species diversity and the 'Shannon–Wiener' Index.
- 746 *Glob. Ecol. Biogeogr.* **12**, 177–179 (2003).
- 747 23. Pearl, J. Causal Diagrams for Empirical Research. *Biometrika* **82**, 669–688 (1995).
- 748 24. Sleep-Related Breathing Disorders in Adults: Recommendations for Syndrome Definition
- and Measurement Techniques in Clinical Research. *Sleep* **22**, 667–689 (1999).
- 750 25. Meijnikman, A. S., Gerdes, V. E., Nieuwdorp, M. & Herrema, H. Evaluating Causality of
- 751 Gut Microbiota in Obesity and Diabetes in Humans. *Endocr. Rev.* **39**, (2018).
- 752 26. Togo, A. H. et al. Description of Mediterraneibacter massiliensis, gen. nov., sp. nov., a new
- 753 genus isolated from the gut microbiota of an obese patient and reclassification of
- 754 Ruminococcus faecis, Ruminococcus lactaris, Ruminococcus torques, Ruminococcus gnavus
- and Clostridium glycyrrhizinilyticum as Mediterraneibacter faecis comb. nov.,
- 756 Mediterraneibacter lactaris comb. nov., Mediterraneibacter torques comb. nov.,
- 757 Mediterraneibacter gnavus comb. nov. and Mediterraneibacter glycyrrhizinilyticus comb.
- 758 nov. Antonie Van Leeuwenhoek **111**, 2107–2128 (2018).

- 759 27. Kaelin, W. G. & Ratcliffe, P. J. Oxygen sensing by metazoans: the central role of the HIF
- 760 hydroxylase pathway. *Mol. Cell* **30**, 393–402 (2008).
- 761 28. Feiner, J. R. et al. High Oxygen Partial Pressure Decreases Anemia-Induced Heart Rate
- 762 Increase Equivalent to Transfusion. *Anesthesiology* **115**, 492–498 (2011).
- 763 29. Vieira-Silva, S. et al. Species-function relationships shape ecological properties of the
- human gut microbiome. *Nat. Microbiol.* **1**, 16088 (2016).
- 30. Selmer, T., Willanzheimer, A. & Hetzel, M. Propionate CoA-transferase from Clostridium
  propionicum. *Eur. J. Biochem.* 269, 372–380 (2002).
- 767 31. Sawers, G. & Watson, G. A glycyl radical solution: oxygen-dependent interconversion of
- 768 pyruvate formate-lyase. *Mol. Microbiol.* **29**, 945–954 (1998).
- 769 32. Dekkers, K. F. et al. An online atlas of human plasma metabolite signatures of gut
- 770 microbiome composition. Preprint at
- 771 https://www.medrxiv.org/content/10.1101/2021.12.23.21268179v1 (2021).
- 33. Priou, P. et al. Independent association between obstructive sleep apnea severity and
- glycated hemoglobin in adults without diabetes. *Diabetes Care* **35**, 1902–1906 (2012).
- 34. Zhang, X., Zhao, A., Sandhu, A. K., Edirisinghe, I. & Burton-Freeman, B. M. Functional
- 775 Deficits in Gut Microbiome of Young and Middle-Aged Adults with Prediabetes Apparent in
- 776 Metabolizing Bioactive (Poly)phenols. *Nutrients* **12**, E3595 (2020).
- 35. Graessler, J. et al. Metagenomic sequencing of the human gut microbiome before and after
- bariatric surgery in obese patients with type 2 diabetes: correlation with inflammatory and
- metabolic parameters. *Pharmacogenomics J.* **13**, 514–522 (2013).
- 780 36. Wong, A.-M. et al. The effect of surgical weight loss on obstructive sleep apnoea: A
- 781 systematic review and meta-analysis. *Sleep Med. Rev.* **42**, 85–99 (2018).

782	37. Ruuskanen, M. O. et al. Gut Microbiome Composition Is Predictive of Incident Type 2
783	Diabetes in a Population Cohort of 5,572 Finnish Adults. Diabetes Care 45, 811-818 (2022).
784	38. Bag, S., Ghosh, T. S. & Das, B. Complete Genome Sequence of Collinsella aerofaciens
785	Isolated from the Gut of a Healthy Indian Subject. Genome Announc. 5, e01361-17 (2017).
786	39. Companys, J. et al. Gut Microbiota Profile and Its Association with Clinical Variables and
787	Dietary Intake in Overweight/Obese and Lean Subjects: A Cross-Sectional Study. Nutrients
788	<b>13</b> , (2021).
789	40. Kim, S. et al. Altered Gut Microbiome Profile in Patients with Pulmonary Arterial
790	Hypertension. Hypertens. Dallas Tex 1979 75, 1063–1071 (2020).
791	41. Galiè, N. et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the
792	Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European
793	Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the
794	International Society of Heart and Lung Transplantation (ISHLT). Eur. Heart J. 30, 2493-
795	2537 (2009).
796	42. Maity, C., Adak, A., Pathak, T. K., Pati, B. R. & Chandra Mondal, K. Study of the cultivable
797	microflora of the large intestine of the rat under varied environmental hyperbaric pressures.
798	J. Microbiol. Immunol. Infect. 45, 281–286 (2012).
799	43. Triplett, J., Braddock, A., Roberts, E., Ellis, D. & Chan, V. Identification of sleep
800	fragmentation-induced gut microbiota alteration and prediction of functional impact in
801	Sprague Dawley rats harboring microbiome derived from multiple human donors. Sleep Sci.
802	Sao Paulo Braz. 15, 07–19 (2022).
803	44. Lin, T. et al. The effect of CPAP treatment on venous lactate and arterial blood gas among
804	obstructive sleep apnea syndrome patients. Sleep Breath. 21, 303–309 (2017).

- 45. Scheiman, J. *et al.* Meta-omics analysis of elite athletes identifies a performance-enhancing
  microbe that functions via lactate metabolism. *Nat. Med.* 25, 1104–1109 (2019).
- 46. Xu, H. et al. Metabolomics Profiling for Obstructive Sleep Apnea and Simple Snorers. Sci.
- 808 *Rep.* **6**, 30958 (2016).
- 47. Poole, D. C., Rossiter, H. B., Brooks, G. A. & Gladden, L. B. The anaerobic threshold: 50+
  years of controversy. *J. Physiol.* 599, 737–767 (2021).
- 48. Muscogiuri, G. *et al.* Gut microbiota: a new path to treat obesity. *Int. J. Obes. Suppl.* 9, 10–
  19 (2019).
- 49. Nielsen, H. B. et al. Identification and assembly of genomes and genetic elements in
- 814 complex metagenomic samples without using reference genomes. *Nat. Biotechnol.* 32, 822–
  815 828 (2014).
- 816 50. Tap, J. *et al.* Identification of an Intestinal Microbiota Signature Associated With Severity of
- 817 Irritable Bowel Syndrome. *Gastroenterology* **152**, 111-123.e8 (2017).
- 818 51. Vangay, P. *et al.* US Immigration Westernizes the Human Gut Microbiome. *Cell* 175, 962819 972.e10 (2018).
- 820 52. Donovan, L. M. & Kapur, V. K. Prevalence and Characteristics of Central Compared to
- 821 Obstructive Sleep Apnea: Analyses from the Sleep Heart Health Study Cohort. *Sleep* **39**,
- 822 1353–1359 (2016).
- 53. Lechat, B. *et al.* Multinight Prevalence, Variability, and Diagnostic Misclassification of
  Obstructive Sleep Apnea. *Am. J. Respir. Crit. Care Med.* 205, 563–569 (2022).
- 54. Li, J. *et al.* Gut microbiota dysbiosis contributes to the development of hypertension.
- 826 *Microbiome* **5**, 14 (2017).

- 55. Pedersen, H. K. *et al.* Human gut microbes impact host serum metabolome and insulin
- 828 sensitivity. *Nature* **535**, 376–381 (2016).
- 829 56. Bergström, G. et al. Prevalence of Subclinical Coronary Artery Atherosclerosis in the
- 830 General Population. *Circulation* **144**, 916–929 (2021).
- 831 57. Byun, J.-I., Song, S. J., Cha, H.-K. & Shin, W. C. Reliability of Manual and Automatic
- 832 Scoring of Single Channel Nasal Airflow Device (ApneaLink) in Determining Moderate or
- 833 Severe Obstructive Sleep Apnea Syndrome. *Sleep Med. Res.* **7**, 68–73 (2016).
- 58. Langmead, B. & Salzberg, S. L. Fast gapped-read alignment with Bowtie 2. *Nat. Methods* 9,
- 835 357–359 (2012).
- 836 59. Li, D., Liu, C.-M., Luo, R., Sadakane, K. & Lam, T.-W. MEGAHIT: an ultra-fast single-
- 837 node solution for large and complex metagenomics assembly via succinct de Bruijn graph.

838 Bioinforma. Oxf. Engl. **31**, 1674–1676 (2015).

- 60. Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. *Bioinforma. Oxf. Engl.* 25, 1754–1760 (2009).
- 61. Brunkwall, L. *et al.* The Malmö Offspring Study (MOS): design, methods and first results.
- 842 *Eur. J. Epidemiol.* **36**, 103–116 (2021).
- 843 62. Pasolli, E. et al. Extensive Unexplored Human Microbiome Diversity Revealed by Over
- 844 150,000 Genomes from Metagenomes Spanning Age, Geography, and Lifestyle. *Cell* 176,
  845 649-662.e20 (2019).
- 63. Haft, D. H. *et al.* RefSeq: an update on prokaryotic genome annotation and curation. *Nucleic*
- 847 *Acids Res.* **46**, D851–D860 (2018).
- 848 64. Huerta-Cepas, J. et al. Fast Genome-Wide Functional Annotation through Orthology
- 849 Assignment by eggNOG-Mapper. *Mol. Biol. Evol.* **34**, 2115–2122 (2017).

- 850 65. Bergström, G. *et al.* The Swedish CArdioPulmonary BioImage Study: objectives and design.
  851 *J. Intern. Med.* 278, 645–659 (2015).
- 852 66. Christensen, S. E. et al. Two New Meal- and Web-Based Interactive Food Frequency
- 853 Questionnaires: Validation of Energy and Macronutrient Intake. J. Med. Internet Res. 15,
- e109 (2013).
- 855 67. Christensen, S. E. et al. Relative Validity of Micronutrient and Fiber Intake Assessed With
- Two New Interactive Meal- and Web-Based Food Frequency Questionnaires. J. Med.
- 857 *Internet Res.* **16**, e59 (2014).
- 858 68. Evans, A. M., DeHaven, C. D., Barrett, T., Mitchell, M. & Milgram, E. Integrated,
- 859 Nontargeted Ultrahigh Performance Liquid Chromatography/Electrospray Ionization
- 860 Tandem Mass Spectrometry Platform for the Identification and Relative Quantification of
- the Small-Molecule Complement of Biological Systems. *Anal. Chem.* **81**, 6656–6667 (2009).
- 862 69. Textor, J., van der Zander, B., Gilthorpe, M. S., Liśkiewicz, M. & Ellison, G. T. Robust
- causal inference using directed acyclic graphs: the R package 'dagitty'. *Int. J. Epidemiol.* **45**,
- 864 1887–1894 (2016).
- 865 70. Bolte, L. A. *et al.* Long-term dietary patterns are associated with pro-inflammatory and anti866 inflammatory features of the gut microbiome. *Gut* **70**, 1287–1298 (2021).
- 867 71. Bowyer, R. C. E. *et al.* Socioeconomic Status and the Gut Microbiome: A TwinsUK Cohort
  868 Study. *Microorganisms* 7, E17 (2019).
- 869 72. Kim, S. ppcor: An R Package for a Fast Calculation to Semi-partial Correlation Coefficients.
  870 *Commun. Stat. Appl. Methods* 22, 665–674 (2015).
- 871 73. R Core Team. R: A language and environment for statistical computing. (2021).

- 872 74. Paradis, E., Claude, J. & Strimmer, K. APE: Analyses of Phylogenetics and Evolution in R
  873 language. *Bioinformatics* 20, 289–290 (2004).
- 75. Benjamini, Y. & Hochberg, Y. Controlling the False Discovery Rate: A Practical and
- 875 Powerful Approach to Multiple Testing. J. R. Stat. Soc. Ser. B Methodol. 57, 289–300
- 876 (1995).
- 877 76. Rubin, D. B. *Multiple Imputation for Nonresponse in Surveys*. (John Wiley & Sons, 2004).
- 878 77. Altman, D. G. & Bland, J. M. Interaction revisited: the difference between two estimates.
  879 *BMJ* 326, 219 (2003).
- 880 78. Canty, A. & Ripley, B. boot: Bootstrap R (S-Plus) Functions. (2021).
- 79. Korotkevich, G. *et al.* Fast gene set enrichment analysis. 060012 (2021) doi:10.1101/060012.
  882

#### 883 Acknowledgements

- 884 We would like to acknowledge the financial support from the European Research Council [ERC-
- 885 2018-STG801965 (TF); ERC-CoG-2014-649021 (MO-M); ERC-STG-2015-679242 (JGS)], the
- 886 Swedish Heart-Lung Foundation [Hjärt-Lungfonden, 2019-0505 (TF); 2020-0485 (EL); 2018-
- 887 0343 (JÄ); 2020-0711 (MO-M); 2020-0173 (GE); 2019-0526 (JGS)], the Swedish Research
- 888 Council [VR, 2019-01471 (TF), 2018-02784 (MO-M), 2019-01015 (JÄ), 2020-00243 (JÄ),
- 2019-01236 (GE), 2021-02273 (JGS)], the Swedish Research Council for Sustainable
- 890 Development [FORMAS, 2020-00989 (SA)], EASD/Novo Nordisk (SA), Göran Gustafsson
- foundation [2016 (TF)], Axel and Signe Lagerman's foundation (TF), and governmental funding
- 892 of clinical research within the Swedish National Health Service (JGS).
- 893 We acknowledge the SCAPIS board for enabling the current study, along with the
- 894 Swedish Heart-Lung Foundation, the main funding body of SCAPIS. Funding for the SCAPIS

895	study was also provided by the Knut and Alice Wallenberg Foundation, the Swedish Research
896	Council and VINNOVA (Sweden's Innovation agency) the University of Gothenburg and
897	Sahlgrenska University Hospital, Karolinska Institutet and Stockholm County council,
898	Linköping University and University Hospital, Lund University and Skåne University Hospital,
899	Umeå University and University Hospital, Uppsala University and University Hospital. The
900	computations and data handling were enabled by resources in project sens2019512 provided by
901	the Swedish National Infrastructure for Computing (SNIC) at Uppsala Multidisciplinary Center
902	for Advanced Computational Science (UPPMAX), partially funded by the Swedish Research
903	Council through grant agreement no. 2018-05973.

#### 904 **Competing interests**

J.B.H. and H.B.N. are currently working at Clinical Microbiomics A/S. J.Ä. has served on the
advisory boards for AstraZeneca and Boehringer Ingelheim and has received lecturing fees from
AstraZeneca and Novartis, all unrelated to the present work. C.B. served as a scientific
consultant for Repha GmBH, Langenhagen, Germany between 2020 and 2021. JS has stock
ownership in companies providing services to Amgen, AstraZeneca, Boehringer, Bayer, Eli
Lilly, Itrim, Janssen, Novo Nordisk, Pfizer and Takeda, outside the submitted work. The
remaining authors declare no competing interests.

# 912 **Contributions**

EL, LL, JS, GB, GE, JGS, JÄ, MO-M and TF obtained the funding for the study. GBa, SS-B, JTH, UH, BK, EL and TF planned and designed the study. JBH and HBN supervised the fecal
samples processing and metagenomics bioinformatics analyses at Clinical Microbiomics S/A.
GBa carried out the statistical analyses with contribution from SS-B, KD, and UH. GBa wrote

917	first version of the manuscript with support from SS-B, JT-H, BK, EL, and TF. All authors
918	contributed with the critical interpretation of the results and critical revision of the manuscript.

## 919 **Figure captions**

920 **Figure 1.** Principal coordinate analysis showing progressive differences in the overall gut

- 921 microbiota composition, measured with Bray-Curtis dissimilarity, across groups of obstructive
- sleep apnea (OSA) severity. Closed circles represent the mean axis value per group and bars
- 923 represent the standard errors. The percentages on the axes labels represent the variance explained
- 924 by each axis. **a**. AHI severity groups. No OSA: AHI < 5; Mild: AHI 5–14.9; Moderate: AHI 15–
- 925 29.9; Severe: AHI  $\geq$  30. **b.** T90 severity groups were defined as one category including
- 926 participants with T90 = 0, and the remaining participants divided by tertiles (t1: T90 = 1-3; t2:
- 927 T90 = 4–14; and t3: T90  $\ge$  15). **c.** ODI severity groups were defined by quartiles of ODI (q1:

928 ODI = 0-1.8; q2: ODI = 1.9-4.3; q3: ODI = 4.4-9.4; and q4: ODI  $\ge 9.5$ ). AHI: apnea-hypopnea

929 index; ODI: oxygen desaturation index; PCo: principal coordinate; T90: percentage of time with
930 oxygen saturation < 90%.</li>

931

932 Figure 2. Number of microbiota species associated with AHI, T90, and/or ODI. Associations 933 investigated using partial Spearman's correlation after removing participants with missing data 934 on covariates. Adjustment for multiple comparisons using the Benjamini-Hochberg method with 935 a 5% false discovery rate. a. Results from the main model (i.e., adjustment for age, sex, smoking, 936 alcohol intake, and DNA extraction plate) not including adjustment for body mass index (BMI) 937 and **b.** including adjustment for BMI. For AHI, n = 3004. For T90 and ODI, n = 3,364. **c.** Results 938 from the extended model (i.e., further adjustment for fiber intake, total energy intake, leisure 939 time physical activity, education, country of birth, and season). For AHI, n = 2,909. For T90 and

940 ODI, n = 3,249. AHI: apnea-hypopnea index; ODI: oxygen desaturation index; T90: percentage
941 of time with oxygen saturation < 90%.</li>

942

943 Figure 3. a. Enrichment for gut metabolic modules (GMM) among the positive associations 944 between T90 and gut microbiota species. The pathway enrichment analysis was conducted on the 945 ranked p-values obtained from Spearman's correlations adjusted for age, sex, alcohol intake, 946 smoking, body mass index, fiber intake, total energy intake, leisure time physical activity, 947 education, country of birth, season, and DNA extraction plate. Multiple comparisons were 948 adjusted for using the Benjamini-Hochberg method. q-values: adjusted p-values considering a 949 5% false discovery rate **b**. Heatmap showing the species associated with T90 or ODI and the 950 T90-enriched  $GMM(^1)$  that were also associated with at least one of the health outcomes: systolic 951 blood pressure (SBP), diastolic blood pressure (DBP), and glycated hemoglobin (Hb1Ac). OSA 952 adj: Spearman's correlation adjusted for age, sex, alcohol intake, smoking, fiber intake, total 953 energy intake, leisure time physical activity, country of birth, apnea-hypopnea index (AHI), 954 oxygen desaturation index, T90, and DNA extraction plate. OSA+BMI adj: additional 955 adjustment for body mass index (BMI). Associations with an asterisk (\*) were identified 956 considering a 5% false discovery rate. NES: normalized enrichment score; OSA: obstructive 957 sleep apnea; T90: percentage of time with oxygen saturation < 90%.

958

Figure 4. Relationship of the T90- and/or ODI-associated species with the plasma metabolome.
T90 and ODI were a. negatively associated with 100 species and b. positively associated with 28
species. The heatmaps show the enriched metabolites groups in the associations between species
and metabolites stratified by the direction of the associations. Enrichment results retrieved from

963	the GUTSY Atlas ( <u>https://gutsyatlas.serve.scilifelab.se/</u> ) <sup>32</sup> . Multiple comparisons were adjusted
964	for using the Benjamini-Hochberg method. Associations with an asterisk (*) were identified
965	considering a false discovery rate of 5%. NES: normalized enrichment score; ODI: oxygen
966	desaturation index; T90: percentage of time with oxygen saturation < 90%.
967	
968	
969	<b>Table 1.</b> Participants' characteristics by obstructive sleep apnea (OSA) severity groups.
970	caption: Continuous variables presented as median [interquartile range] and categorical
971	variables presented as absolute numbers (%). AHI: apnea-hypopnea index; BMI: Body mass
972	index; DBP: diastolic blood pressure; ESS: Epworth sleepiness scale; HbA1c: glycated
973	hemoglobin; med.: medication; ODI: oxygen desaturation index; PPI: proton-pump inhibitors;
974	SBP: systolic blood pressure; T90: percentage of time with oxygen saturation < 90%; WHR:
975	waist-hip-ratio. <sup>a</sup> Percentages do not add to 100% as participants with incomplete compulsory
976	education were not included in the table.
977	
978	Supplementary Figures captions
979	Figure S1. Study flowchart for the 4,839 SCAPIS-Uppsala participants with available data on
980	their gut microbiota composition.
981	
982	Figure S2. Directed acyclic graph depicting the causal assumptions on the effect of obstructive
983	sleep apnea (OSA) on the gut microbiota composition. A directed edge (or "arrow") from one
984	node to another represents a direct effect between these two nodes. Green line: causal path; pink


985 line: biasing path; pink nodes: ancestor of exposure and outcome; and blue nodes: ancestor of986 outcome.

987

- 988 Figure S3. Directed acyclic graph depicting the causal assumptions on the effect of gut
- 989 microbiota on blood pressure measurements and insulin resistance. A directed edge (or "arrow")
- 990 from one node to another represents a direct effect between these two nodes. Green line: causal
- path; pink line: biasing path; pink nodes: ancestor of exposure and outcome; and blue nodes:
- ancestor of outcome.

# 994 Table 1.

	All	No OSA (AHI < 5/h)	Mild (AHI 5–14.9/h)	Moderate (AHI 15–29.9/h)	Severe $(AHI \ge 30/h)$
N	3,175	1,851 (58.3%)	899 (28.3%)	295 (9.3%)	130 (4.1%)
Age (years)	57.7 [53.9;61.4]	56.8 [53.2;61.0]	58.8 [54.9;62.0]	59.4 [55.7;62.5]	59.5 [55.5;61.7]
Female	1,708 (53.8%)	1,122 (60.6%)	446 (49.6%)	98 (33.2%)	42 (32.3%)
AHI (events/h)	3.8 [1.5;8.6]	1.7 [0.9;3.1]	7.8 [6.2;10.4]	20.1 [17.2;24.1]	38.0 [33.8;49.4]
ODI (events/h)	4.1 [1.7;9.2]	2.1 [1.0;3.6]	8.3 [6.0;11.0]	19.1 [15.3;23.7]	35.5 [29.2;42.6]
T90 (%)	2.0 [0.0;12.0]	1.0 [0.0;4.0]	5.0 [2.0;18.0]	12.0 [6.0;25.0]	20.0 [11.0;41.8]
BMI (kg/m <sup>2</sup> )	26.3 [24.0;29.2]	25.2 [23.1;27.7]	27.5 [25.2;30.3]	28.9 [26.1;32.2]	30.0 [27.4;34.2]
WHR	0.9 [0.9;1.0]	0.9 [0.8;1.0]	0.9 [0.9;1.0]	1.0 [0.9;1.0]	1.0 [0.9;1.0]
Shannon index	4.2 [3.9;4.4]	4.2 [4.0;4.4]	4.1 [3.8;4.4]	4.1 [3.9;4.4]	4.0 [3.6;4.2]
SBP (mmHg)	124 [114;135]	121 [112;131]	127 [116;138]	129 [118;140]	132 [120;144]
DBP (mmgHg)	76 [70;84]	75 [68;81]	78 [72;85]	80 [74;88]	82 [74;88]
HbA1c (mmol/mol)	35 [33;38]	35 [33;37]	36 [34;38]	36 [34;39]	38 [35;41]
Hemoglobin (g/L) Current smoker	141 [133;150] 249 (8.3%)	139 [132;147] 137 (7.8%)	142 [134;151] 79 (9.3%)	146 [138;154] 20 (7.2%)	146 [139;153] 13 (10.9%)
Alcohol intake (g/day)	5.5 [1.9;10.2]	5.2 [1.8;9.3]	6.1 [2.2;11.2]	7.2 [2.5;13.0]	6.3 [1.2;12.8]
Fiber (g/day)	18.3 [13.1;25.1]	19.2 [13.7;26.1]	17.3 [12.4;23.5]	17.5 [12.3;23.4]	16.8 [12.8;23.8]
Total energy intake (kcal/day)	1,611 [1,267;2,014]	1,624 [1,289;2,039]	1,594 [1,240;1,983]	1,593 [1,198;2,000]	1,672 [1,278;2,067]
Leisure time physical activity					
mostly sedentary	306 (10.3%)	135 (7.7%)	106 (12.6%)	41 (14.8%)	24 (19.8%)
moderate activity	1,369 (45.9%)	749 (42.8%)	425 (50.7%)	137 (49.5%)	58 (47.9%)
regular and moderate activity	964 (32.3%)	622 (35.6%)	238 (28.4%)	74 (26.7%)	30 (24.8%)
regular exercise or training	346 (11.6%)	243 (13.9%)	69 (8.2%)	25 (9.0%)	9 (7.4%)
Highest education <sup>a</sup>					
Compulsory	191 (6.3%)	82 (4.6%)	65 (7.5%)	32 (11.3%)	12 (9.9%)
Upper secondary	247 (41.0%)	681 (38.3%)	368 (42.7%)	136 (48.2%)	62 (51.2%)
University	1,593 (52.3%)	1,012 (56.9%)	421 (48.8%)	113 (40.1%)	47 (38.8%)
Birth place					
Scandinavia	2,861 (90.4%)	1,670 (90.5%)	809 (90.3%)	264 (89.5%)	118 (90.8%)
Europe	123 (3.9%)	73 (4.0%)	30 (3.3%)	15 (5.1%)	5 (3.8%)
Asia	112 (3.5%)	61 (3.3%)	37 (4.1%)	9 (3.1%)	5 (3.8%)
Other	70 (2.2%)	41 (2.2%)	20 (2.2%)	7 (2.4%)	2 (1.5%)
Type 2 diabetes	253 (8.0%)	106 (5.7%)	90 (10.0%)	28 (9.5%)	29 (22.3%)
Hypertension	674 (21.2%)	292 (15.8%)	235 (26.1%)	104 (35.3%)	43 (33.1%)
Hyperlipidemia	368 (11.6%)	169 (9.13%)	124 (13.8%)	52 (17.6%)	23 (17.7%)
Medication					
metformin	91 (2.9%)	30 (1.6%)	38 (4.2%)	9 (3.1%)	14 (10.8%)
antihypertensive med.	585 (18.4%)	244 (13.2%)	207 (23.0%)	92 (31.2%)	42 (32.3%)
hyperlipidemia med.	236 (7.4%)	92 (5.0%)	90 (10.0%)	37 (12.5%)	17 (13.1%)
PPI	94 (3.0%)	42 (2.3%)	25 (2.8%)	19 (6.4%)	8 (6.2%)
ESS	6 [3;9]	5 [3;8]	6 [3;9]	6 [4;10]	6 [4;10]





→ t2 (n = 759)

Moderate (n = 295)

Severe (n = 130)

- **---** q3 (n = 891)





\*

\*

\*

190 OD WINGBER WINGBER

Eubacteriales sp. (HG3A.0331)

Eubacteriales sp. (HG3A.0120)

Eubacteriales sp. (HG3A.0084)

Eubacteriales sp. (HG3A.0085)

Eubacteriales sp. (HG3A.0193)

Intestinimonas massiliensis


0.1

0.05

-0.05

-0 1

0



b


< 0.05

>0.05


Gut metabolic modules

а

#### Species in negative association with T90/ODI



#### Species in positive association with T90/ODI



b